DOV Revamps Phase III Trial Population For Bicifadine
This article was originally published in The Pink Sheet Daily
Executive Summary
An NDA submission for the chronic lower back pain agent, expected in the first half of 2007, is postponed.
You may also be interested in...
DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.
DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.
DOV Stresses “Residual Value” Of Bicifadine In Chronic Pain Despite Initial Phase III Failure
Firm had planned an NDA filing in the first half of 2007 for use of the non-opioid analgesic for chronic low back pain.